The law firm is examining whether these proposed mergers and acquisitions offer fair value or if insiders stand to gain at the expense of ordinary investors. Specifically, the inquiry focuses on the $73.00 per share cash sale of Bio-Techne to Merck KGaA and the $135.11 per share cash deal between Apogee Therapeutics and AbbVie. Attorneys are evaluating whether these terms unfairly restrict superior competing offers or contain hidden financial benefits for company leadership.

Investigations also extend to the merger agreements involving Boundless Bio and Chicago Atlantic Real Estate Finance. In the Boundless Bio deal, shareholders are slated to hold a 3.7% stake in the newly combined entity, while REFI investors are expected to retain approximately 50.5% ownership in their merger with Chicago Atlantic BDC. Halper Sadeh representatives stated they may seek increased consideration or additional disclosures for those impacted by these corporate restructurings.